Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Munir, Janmohamed"'
Autor:
David G. Rosenthal, Purvi Parwani, Tyler O. Murray, Bradley J. Petek, Bryan S. Benn, Teresa De Marco, Edward P. Gerstenfeld, Munir Janmohamed, Liviu Klein, Byron K. Lee, Joshua D. Moss, Melvin M. Scheinman, Henry H. Hsia, Van Selby, Laura L. Koth, Miguel H. Pampaloni, Julie Zikherman, Vasanth Vedantham
Publikováno v:
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, Vol 8, Iss 18 (2019)
Background Long‐term corticosteroid therapy is the standard of care for treatment of cardiac sarcoidosis (CS). The efficacy of long‐term corticosteroid‐sparing immunosuppression in CS is unknown. The goal of this study was to assess the efficac
Externí odkaz:
https://doaj.org/article/09fd97b1b98040e68be6b46ddabcdac0
Autor:
M., Fanous Sherif1 (AUTHOR) sherif.fanous@ucsf.edu, Munir, Janmohamed2 (AUTHOR)
Publikováno v:
American Journal of Health-System Pharmacy. 12/1/2018, Vol. 75 Issue 23, p1877-1881. 5p. 2 Charts.
Autor:
Munir Janmohamed, Sherif M. Fanous
Publikováno v:
American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists. 75(23)
Purpose Safe transition of patients with pulmonary arterial hypertension (PAH) from parenteral treprostinil to oral selexipag therapy in both inpatient and outpatient settings is described. Summary There is a paucity of published data on how to safel
Autor:
Micah R. Fisher, Chad Miller, Colleen McEvoy, David Poch, Adaani E. Frost, Raymond L. Benza, Munir Janmohamed, John W. McConnell, Harrison W. Farber, Thomas Pfister, Terry Fortin, Kelly Chin, Vallerie V. McLaughlin, Yoko Shiraga, Jason S. Fritz, Michael Eggert, Nick H. Kim
Publikováno v:
The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation. 38(1)
BACKGROUND A long-term trial showed that the oral prostacyclin (PGl 2 ) receptor (IP) agonist, selexipag , delayed disease progression in patients with pulmonary arterial hypertension (PAH). Transition to selexipag in patients treated with more burde
Publikováno v:
Cardiology. 115:205-208
Background: Pulmonary hypertension carries significant maternal and fetal risk during pregnancy and the postpartum period. As maternal mortality is high, specific targeted therapy for pulmonary hypertension may be required during pregnancy. Cases: We
Autor:
Uri Elkayam, Munir Janmohamed, Lee-Jen Wei, Roger M. Mills, J. Thomas Heywood, Parta Hatamizadeh
Publikováno v:
Clinical Cardiology. 32:215-219
Background We assessed the effect of increases in serum creatinine on mortality in nesiritide-treated versus control subjects with acute decompensated heart failure (ADHF). Hypothesis Mortality effect of nesiritide-related increases in serum creatini
Publikováno v:
Circulation. 117:200-205
Background— A “renal dose” of dopamine is often used to increase renal blood flow; however, data on the magnitude of effect and site of action in patients with heart failure are scarce. Methods and Results— Renal effects of intravenous dopami
Autor:
Sandra Illum, Kalgi Modi, Sorel Goland, Munir Janmohamed, Fahed Bitar, James Mirocha, Uri Elkayam, Lawrence S.C. Czer, Parta Hatamizadeh
Publikováno v:
Journal of cardiac failure. 15(8)
Background Clinical profile and predictors of major adverse events (MAE) associated with peripartum cardiomyopathy (PPCM) have not been characterized. Methods and Results A retrospective review and analysis of clinical data of 182 patients with PPCM.
Publikováno v:
Circulation. 118
Drs Lema and Canessa point out the important intersubject variability of plasma levels of dopamine, which has been shown in normal volunteers. These differences may also be related …
Publikováno v:
Critical care medicine. 36
Recent guidelines by the Heart Failure Society of America have recommended consideration for use of nitroprusside, nitroglycerin, or nesiritide in addition to diuretics to achieve hemodynamic and symptomatic improvement. This article reviews the resu